Cellectar Biosciences has been granted orphan drug designation for its therapeutic, CLR 131, by the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for the treatment of neuroblastoma,…
The U.S. Patent and Trademark Office awarded Cellectar Biosciences a notice of allowance for a patent covering the use of CLR 131 in multiple myeloma (MM), the company announced today. “This patent…
Cellectar Biosciences has extended its collaboration with Pierre Fabre, a French pharmaceutical company, the company announced today. “The extension of our research agreement with Pierre Fabre allows us to further…
Cellectar Biosciences announced today it has entered into a strategic collaboration with Onconova Therapeutics, a biopharmaceutical company, to develop new phospholipid drug conjugates (PDC). According to a release, the Newtown,…
Cellectar Biosciences‘ Phospholipid Drug Conjugate (PDC) research program has generated numerous PDC molecules that show “significant” improved pharmacologic activity, the company announced today. According to a release, Cellectar’s research demonstrates that…
Cellectar Biosciences’ CLR 131 has achieved an overall survival of greater than 22 months in advanced multiple myeloma patients, the company announced today. “We continue to make meaningful progress on…
Cellectar Biosciences announced today that it will collaborate with Avicenna Oncology, a clinical stage biotechnology company based in Switzerland, to develop new phospholipid drug conjugates for solid tumors. According to…
Cellectar Biosciences added Douglas Swirsky and Frederick Driscoll to its board of directors, the company announced recently. Swirsky is the president and CEO of GenVec and has worked at Stifel Nicolaus…
Cellectar Biosciences announced today its initiation of a Phase II clinical study of CLR 131 in patients with multiple myeloma and other hemotologic malignancies. According to a release, the study…
Cellectar Biosciences announced today the Japanese Patent Office has granted a composition of matter patent for its optical imaging phospholipid drug conjugates (PDCs), CLR 1501 and CLR 1502. “This patent…
